$ASMB

Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Assembly Biosciences (NASDAQ: ASMB) has received a "Moderate Buy" consensus recommendation from seven research firms, with an average 12-month target price of $41.75. The biopharmaceutical company, focused on hepatitis B and D therapies, saw its shares open up 10.7% at $28.75. Institutional investors have significantly increased their stakes in the company, with hedge funds owning 19.92% of the stock.

Original reporting
MarketBeat · MarketBeat
Published Feb 21, 2026, 8:52 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 21, 2026, 9:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Recommendation of "Moderate Buy" from Analysts — source image
Decision brief

The 30-second read

$ASMBBullishMed
01

Why it matters

The positive analyst consensus and increased institutional ownership suggest a favorable outlook, potentially leading to short- to medium-term stock appreciation.

02

Market read

The news is highly relevant for investors interested in biotech and pharma stocks, especially those focusing on hepatitis treatments.

03

What to watch

Potential regulatory hurdles, clinical trial results, or competition in hepatitis therapies could impact stock performance.

Timing: Immediate to short-term (next 1-3 months)

Background

Assembly Biosciences specializes in developing therapies for hepatitis B and D, with recent positive analyst sentiment boosting investor confidence.

Company-level read

Ticker impact

$ASMBBullishHigh confidence
Context

High relevance due to recent analyst upgrade and institutional interest.

Expected impact

Moderate upward price movement expected over the next 3-6 months.

Evidence & confidence

The consensus recommendation and increased institutional holdings suggest positive market sentiment and growth prospects, supported by the company's focus on hepatitis therapies and favorable analyst targets.

Market effects

Potential positive influence on biotech and pharmaceutical sectors, especially hepatitis-focused companies.

Primarily US-based market impact, with possible ripple effects in global biotech indices.

Limited; specific to US biotech sector, but may influence global biotech investor sentiment.

Counterpoint

Some analysts may view the 'Moderate Buy' rating as overly optimistic given the company's current valuation and sector volatility.

Key entities

  • Assembly Biosciences

    Biopharmaceutical company focused on hepatitis B and D therapies.

  • MarketBeat

    Provider of financial news and analyst ratings.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.